Actively Recruiting
Chemoimmunotherapy Followed by Surgery for Oligometastatic Esophagogastric Cancer: (TORO Protocol)
Led by University Health Network, Toronto · Updated on 2025-05-16
72
Participants Needed
1
Research Sites
521 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Esophageal cancer and cancers of the gastroesophageal junction (GEJ) are among the most common malignancies worldwide. The outcome for these patients remains very poor. Patients with limited spread of their cancer (oligometastatic disease) have a better prognosis than those with widespread disease. Recent advances in treatment therapies, including use of pre-operative immunotherapy, surgery and/or targeted radiation (SBRT) may help to prolong lifespan in patients with oligometastatic disease. Patients will undergo treatment for their oligometastatic esophageal or gastric cancer with pre-operative chemoimmunotherapy followed by surgery and possibly SBRT to evaluate the value of adding surgery and possibly SBRT to their treatment.
CONDITIONS
Official Title
Chemoimmunotherapy Followed by Surgery for Oligometastatic Esophagogastric Cancer: (TORO Protocol)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged over 18 and under 80 years
- Histologically confirmed adenocarcinoma or squamous cell carcinoma of the esophagus or gastroesophageal junction
- Oligometastatic disease defined as up to five metastatic lesions treatable by surgery or radiation, located in a maximum of two organs
- ECOG Performance Status of 0 or 1
- Adequate heart and lung function based on tests
- Adequate blood counts suitable for systemic therapy
- Adequate kidney and liver function
- Negative pregnancy test for women of childbearing potential
You will not qualify if you...
- Presence of widespread peritoneal or pleural cancer spread
- Positive tumor cells in peritoneal fluid at enrollment (except if previously positive but now negative after treatment)
- Multiple bone or brain metastases, though one solitary bone or brain metastasis is allowed if treatable with radiotherapy
- Any condition making the patient unfit for surgery, radiation, or chemotherapy
- Active autoimmune disease requiring systemic treatment in the past 2 years (except vitiligo or resolved childhood asthma/atopy)
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Toronto General Hospital, University Health Network
Toronto, Ontario, Canada, M5G 2C4
Actively Recruiting
Research Team
F
Frances Allison
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here